[go: up one dir, main page]

AR074330A1 - Nuevo procedimiento para la preparacion de granulos de principios activos y granulos asi obtenidos - Google Patents

Nuevo procedimiento para la preparacion de granulos de principios activos y granulos asi obtenidos

Info

Publication number
AR074330A1
AR074330A1 ARP090104388A ARP090104388A AR074330A1 AR 074330 A1 AR074330 A1 AR 074330A1 AR P090104388 A ARP090104388 A AR P090104388A AR P090104388 A ARP090104388 A AR P090104388A AR 074330 A1 AR074330 A1 AR 074330A1
Authority
AR
Argentina
Prior art keywords
granulate
granules
active principles
stage
polyols
Prior art date
Application number
ARP090104388A
Other languages
English (en)
Inventor
Pascal Suplie
Christophe Lebon
Original Assignee
Debregeas Et Associes Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40348849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR074330(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debregeas Et Associes Pharma filed Critical Debregeas Et Associes Pharma
Publication of AR074330A1 publication Critical patent/AR074330A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Glanulating (AREA)
  • Fertilizers (AREA)
  • Seasonings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a un procedimiento de preparación de un granulado de, al menos, dos principios activos, que comprende una etapa de aplicación por polvificado de dichos principios activos sobre un soporte particular sólido, y dichos principios activos no son extractos de plantas. Reivindicación 2: Procedimiento de acuerdo con la reivindicación 1, caracterizado porque la etapa de polvificado comprende la pulverización de una solución acuosa, alcohólica o hidroalcohólica de un aglutinante. Reivindicación 3: Procedimiento de acuerdo con la reivindicación 1 o 2, caracterizado porque comprende, después de la etapa de polvificado, una etapa de recubrimiento del granulado, en especial, depositando por peliculado el agente de recubrimiento en forma de película sobre el granulado, seguida dado el caso, de una etapa de mezclado con un lubricante y/o un aromatizante y/o un edulcorante y/o un colorante. Reivindicación 4: Procedimiento de acuerdo con cualquiera de las reivindicaciones 1 a 3, en el cual el soporte se elige en el grupo constituido por polioles tales como manitol, sorbitol, maltitol o xilitol, lactosa, fosfato dicálcico, carbonatos, tales como carbonato de calcio, de potasio, de magnesio o de sodio, gluconatos, silicatos, cristales de azúcar, sacarosa y derivados de sílice. Reivindicación 5: Procedimiento de acuerdo con cualquiera de las reivindicaciones 2 a 4, en el cual el aglutinante se elige en el grupo constituido por almidón, sacarosa, goma arábiga, polivinilpirrolidona, hidroxipropilmetilcelulosa, goma laca, hidrocipropilcelulosa, celulosa, polioles, alginatos, glicéridos poliglicolizados o macrogolglicéridos, en especial, macrogolglicéridos de estearoílo. Reivindicación 8: Granulado de acuerdo con la reivindicación 7, caracterizado porque el núcleo sólido no es un núcleo neutro.
ARP090104388A 2008-11-14 2009-11-13 Nuevo procedimiento para la preparacion de granulos de principios activos y granulos asi obtenidos AR074330A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0857764A FR2938432B1 (fr) 2008-11-14 2008-11-14 Nouveau procede de preparation de granules de principes actifs, et granules tels qu'obtenus

Publications (1)

Publication Number Publication Date
AR074330A1 true AR074330A1 (es) 2011-01-05

Family

ID=40348849

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104388A AR074330A1 (es) 2008-11-14 2009-11-13 Nuevo procedimiento para la preparacion de granulos de principios activos y granulos asi obtenidos

Country Status (25)

Country Link
US (1) US20110280945A1 (es)
EP (1) EP2349226A1 (es)
JP (1) JP5608681B2 (es)
KR (1) KR101585705B1 (es)
CN (1) CN102223879A (es)
AR (1) AR074330A1 (es)
AU (1) AU2009315449B2 (es)
BR (1) BRPI0916019A2 (es)
CA (1) CA2743753A1 (es)
CL (1) CL2011001115A1 (es)
CO (1) CO6382108A2 (es)
CU (1) CU20110107A7 (es)
EA (1) EA201100757A1 (es)
FR (1) FR2938432B1 (es)
IL (1) IL212850A0 (es)
MA (1) MA32789B1 (es)
MX (1) MX2011005072A (es)
NZ (1) NZ592857A (es)
PE (1) PE20110945A1 (es)
SG (1) SG195651A1 (es)
TN (1) TN2011000235A1 (es)
TW (1) TWI522113B (es)
UA (1) UA103781C2 (es)
WO (1) WO2010055268A1 (es)
ZA (1) ZA201103543B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2971422B1 (fr) * 2011-02-11 2016-05-20 Debregeas Et Associes Pharma Granules d'acide gamma-hydroxybutyrique
US9241956B2 (en) * 2012-11-05 2016-01-26 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
US20140127296A1 (en) * 2012-11-05 2014-05-08 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
US11058635B1 (en) * 2020-10-15 2021-07-13 King Abdulaziz University Oral administration of 5-FU in a gelling nanosuspension for targeted delivery to treat colorectal cancers
KR20240157168A (ko) * 2023-04-24 2024-11-01 주식회사 케이티앤지 바인더를 사용하는 파우치 충진 물질의 제조 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6327424A (ja) * 1986-07-17 1988-02-05 Shionogi & Co Ltd 徐放性製剤およびその製造法
JP2820829B2 (ja) * 1991-03-07 1998-11-05 武田薬品工業株式会社 有核散剤およびその製造方法
JPH08310969A (ja) * 1995-05-22 1996-11-26 Lion Corp 固形薬品組成物及びその製造方法
FR2790668B1 (fr) * 1999-03-12 2002-07-26 D B F Granules contenant une substance vegetale et leur procede de preparation
MXPA01011800A (es) * 1999-05-17 2003-08-19 D B F Granulos que contienen una sustancia vegetal y procedimiento para prepararlos.
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US9247765B2 (en) * 2004-01-14 2016-02-02 Omniactive Health Technologies Limited Stable beadlets of lipophilic nutrients
FR2880541B1 (fr) * 2005-01-10 2008-02-22 Amalric Veret Une nouvelle formule de plantes sous forme de micro-granules de xilitol pour renforcer les effets des plantes et leurs proprietes par une meilleure assimilation
US20060182796A1 (en) * 2005-02-03 2006-08-17 Abrika Pharmaceuticals, Inc. Taste masked pharmaceutical compositions
WO2008027993A2 (en) * 2006-08-31 2008-03-06 Eurand, Inc. Drug delivery systems comprising solid solutions of weakly basic drugs
KR101180163B1 (ko) * 2007-02-14 2012-09-05 다이니치 세이카 고교 가부시키가이샤 유기안료의 분산제 및 그 사용
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system

Also Published As

Publication number Publication date
SG195651A1 (en) 2013-12-30
PE20110945A1 (es) 2012-02-01
MX2011005072A (es) 2011-10-03
TN2011000235A1 (fr) 2012-12-17
TW201029667A (en) 2010-08-16
EA201100757A1 (ru) 2011-12-30
ZA201103543B (en) 2012-01-25
NZ592857A (en) 2013-07-26
WO2010055268A1 (fr) 2010-05-20
BRPI0916019A2 (pt) 2015-11-10
AU2009315449B2 (en) 2015-03-26
CO6382108A2 (es) 2012-02-15
CN102223879A (zh) 2011-10-19
US20110280945A1 (en) 2011-11-17
CL2011001115A1 (es) 2011-11-11
JP5608681B2 (ja) 2014-10-15
IL212850A0 (en) 2011-07-31
JP2012508786A (ja) 2012-04-12
FR2938432A1 (fr) 2010-05-21
EP2349226A1 (fr) 2011-08-03
UA103781C2 (uk) 2013-11-25
CA2743753A1 (fr) 2010-05-20
MA32789B1 (fr) 2011-11-01
KR20110095888A (ko) 2011-08-25
CU20110107A7 (es) 2012-01-31
TWI522113B (zh) 2016-02-21
KR101585705B1 (ko) 2016-01-15
FR2938432B1 (fr) 2011-05-20
AU2009315449A1 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
AR074330A1 (es) Nuevo procedimiento para la preparacion de granulos de principios activos y granulos asi obtenidos
AR074351A1 (es) Composicion a base de acido gamma-hidroxibutirico
WO2010025931A3 (en) Pharmaceutical combination of 3- (3-dimethylamino-1-ethyl-2 -methyl-propyl) - phenol and an antiepileptic
CL2011001853A1 (es) Uso de una combinacion farmaceutica que comprende linagliptina y un segundo agente antidiabetico seleccionado entre biguanidas, tiazolidindionas, sulfonilureas, glinidas, entre otros, y, opcionalmente, un tercer agente antidiabetico, para tratar diabetes mellitus tipo 2 y complicaciones de la diabetes, entre otras.
HK1247843A1 (zh) 具有受控吸收曲线的用於口服给药活性剂的制剂
BR112012000492A2 (pt) composição detergente moderadamente alcalina, com baixos teores de coadjuvantes que compreende ácido fitalimido peroxicaproico para tratamento de tecido sólido
EP1932530A4 (en) MEANS FOR IMPROVING COLLAGEN PRODUCTION AND ITS USE
NI200800318A (es) Composiciones farmacéuticas estabilizadas que comprenden fesoterodina.
WO2009147402A3 (en) Compositions comprising honey and a super- absorbent material
BRPI0924136B8 (pt) composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma
WO2009149224A3 (en) Elastase treatment of tissue matrices
WO2010030704A3 (en) Antibacterial aminoglycoside analogs
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
NZ600271A (en) Lyophilization methods, compositions, and kits
WO2009143845A3 (en) Flavor impregnation of a chewing gum core
WO2010132765A3 (en) Antibacterial aminoglycoside analogs
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
BRPI0614545B8 (pt) composição farmacêutica de liberação controlada, seu processo de produção, forma de dosagem oral com revestimento entérico de pacreatina e uso da mesma
WO2010043408A3 (de) Mikroverkapseltes fesoterodin
WO2007042271A8 (en) Nutraceutical composition for the treatment of muscle wasting
WO2006074226A3 (en) Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof
WO2012073170A3 (fr) Composition galénique adaptée à l'administration à un animal non-humain, utilisations de celle-ci et méthodes associées
WO2010062122A2 (ko) 동맥경화 예방 또는 치료용 조성물
WO2008005560A8 (en) Prevention of thrombotic disorders with active vitamin d compounds

Legal Events

Date Code Title Description
FB Suspension of granting procedure